IceCure Medical has advanced its expansion efforts in the Chinese market with a new regulatory submission to the National Medical Products Administration (NMPA) for its ProSense cryoablation system, a sophisticated tumor destruction platform designed for minimally invasive procedures.
The regulatory filing represents a significant enhancement to IceCure's existing presence in China, where their IceSense3 system has already gained regulatory approval. The new submission encompasses an expanded portfolio of five distinct cryoprobes, each engineered with specific diameters, lengths, and ice ball formations to address various surgical needs.
Technological Innovation in Tumor Treatment
The ProSense system employs advanced liquid nitrogen technology to generate extensive lethal zones capable of destroying both benign and malignant lesions. The procedure involves precise insertion of a cryoprobe into the target tumor under CT or ultrasound guidance, followed by the application of sub-zero temperatures that create an ice ball formation. This controlled freezing process effectively diminishes the tumor while preserving surrounding healthy tissue, with the body naturally absorbing the necrotic tissue over time.
Versatile Clinical Applications
The system's versatility extends across multiple medical specialties, including:
- General surgery (breast and lung tissues)
- Oncology
- Dermatology
- Urology
- Proctology
- Gynecology
Practical Clinical Benefits
ProSense's transportable design and efficient procedure times make it particularly suitable for office-based treatments, especially in breast tumor cases. The system's single cryoprobe approach streamlines the surgical process, potentially reducing complications and accelerating patient recovery.
Eyal Shamir, CEO of IceCure Medical, emphasized the strategic importance of the Chinese market, stating, "China is potentially a very large market for cryoablation and we are moving forward with an expanded line of available products, as well as securing reimbursement so that IceCure can be ideally positioned to serve this important geography."
The ProSense Cryoablation System has already established a global presence with regulatory approvals in Europe, China, and the United States for various clinical indications. This latest NMPA application aims to further strengthen IceCure's position in the rapidly evolving Chinese medical device market.
